Andere Kunden interessierten sich auch für
![EGFR Targeted Gemcitabine PLGA Nanoparticles for Pancreatic Cancer]( "EGFR Targeted Gemcitabine PLGA Nanoparticles for Pancreatic Cancer")
EGFR Targeted Gemcitabine PLGA Nanoparticles for Pancreatic Cancer40,99 €![Fabrication of SR Matrix Tablet for Arthritis Treatment]( "Fabrication of SR Matrix Tablet for Arthritis Treatment")
Fabrication of SR Matrix Tablet for Arthritis Treatment32,99 €![Fabrication of interpenetrating polymer network hydrogel microspheres]( "Fabrication of interpenetrating polymer network hydrogel microspheres")
Fabrication of interpenetrating polymer network hydrogel microspheres38,99 €![Synthesis And Pharmacological Screening Of Quinoxaline Derivatives]( "Synthesis And Pharmacological Screening Of Quinoxaline Derivatives")
Synthesis And Pharmacological Screening Of Quinoxaline Derivatives32,99 €![Fabrication of dosage form leads to decrease in cost of the therapy]( "Fabrication of dosage form leads to decrease in cost of the therapy")
Fabrication of dosage form leads to decrease in cost of the therapy32,99 €![Synthesis & pharmacological evaluation of novel hydrazone derivatives]( "Synthesis & pharmacological evaluation of novel hydrazone derivatives")
Synthesis & pharmacological evaluation of novel hydrazone derivatives32,99 €![Binding Between Protein and Drugs and Second Derivatives Application]( "Binding Between Protein and Drugs and Second Derivatives Application")
Binding Between Protein and Drugs and Second Derivatives Application42,99 €
Gemcitabine is a nucleoside analogue, used in various carcinomas such as non small cell lung cancer, pancreatic cancer, ovarian cancer and breast cancer. The major setbacks to the conventional therapy with gemcitabine include its short half-life and highly hydrophilic nature. The objectives of this investigation were to synthesize lipophilic derivative of gemcitabine, evaluate the physiochemical properties, entrapment efficiency, in vitro release, cytotoxicity, and cellular uptake of nanoparticulate formulations containing gemcitabine and stearoyl gemcitabine. We successfully prepared a formulation providing dual protection of gemcitabine against chemical decomposition from plasma catabolism and improve metabolic stability, first by covalently linking the amino group of gemcitabine to a long fatty chain, and then by encapsulating this lipophilic derivative in the formulations. PLGA nanoparticles can act as carriers for both lipophilic and hydrophilic drugs.